Egis Posts Low Growth For Fiscal Year But Long-term Outlook More PositiveNovember 2010 | Industry Trend Analysis
BMI View: Hungary-based Egis has posted weak financial figures for its 2009/10 business year. The company's financial results are based on revenues from October 1 2009 to September 30 2010. Despite strong export growth in Russia and the Commonwealth of Independent States (CIS), poor domestic sales and a contraction of exports to other countries has led to a weak sales growth performance. However, BMI believes Egis will outperform its global peers over the medium-to-long term. Compared to drugmakers with a high exposure to Western Europe and the US, BMI believes Egis is well positioned geographically to exploit higher pharmaceutical expenditure growth forecasts in Central and Eastern Europe (CEE).
To read the full article, please choose one of the following options: